New Delhi, Sep 13 (PTI) Shares of Advanced Enzyme Technologies on Monday zoomed over 12 per cent after the company said its systemic enzyme and probiotic supplements have passed randomised controlled clinical trials in terms of efficacy to resolve post-COVID fatigue symptoms.

The stock jumped 12.40 per cent to close at Rs 412.30 on the BSE. During the day, it gained 15.04 per cent to Rs 422.

Also Read | Alcheminers Halal Investment Creating Opportunities for Islamic Investors.

On the NSE, it jumped 12.48 per cent to close at Rs 412.30.

With an aim to evaluate the efficacy and safety of the health supplements -- ImmunoSEB and ProbioSEB CSC3 -- in patients suffering from COVID-19, induced fatigue, randomised, multi-centric, double-blind, and placebo-controlled trials were conducted in 200 patients suffering from post-COVID fatigue symptoms, Advanced Enzyme Technologies Ltd (AETL) said in a regulatory filing on Monday.

Also Read | Jet Airways Shares Jump 5% After the Company Announces To Restart Domestic Operations in 2022.

The clinical study demonstrated that the 14-day supplementation of ImmunoSEB and ProbioSEB CSC3 resolved post-COVID-19 fatigue symptoms and improved patients' functional status and quality of life, it added.

"Enzymes and probiotics are a robust mechanism to revitalize stamina and vitality, which is proved during the recently concluded randomised clinical trials," AETL Chairman Vasant Rathi said.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)